Premium
IL ‐1 and IL ‐1 regulatory pathways in cancer progression and therapy
Author(s) -
Mantovani Alberto,
Barajon Isabella,
Garlanda Cecilia
Publication year - 2018
Publication title -
immunological reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.839
H-Index - 223
eISSN - 1600-065X
pISSN - 0105-2896
DOI - 10.1111/imr.12614
Subject(s) - inflammation , angiogenesis , cancer research , tumor progression , cytokine , tumor microenvironment , carcinogenesis , biology , metastasis , decoy , immunology , cancer , receptor , tumor necrosis factor alpha , tumor cells , biochemistry , genetics
Summary Inflammation is an important component of the tumor microenvironment. IL ‐1 is an inflammatory cytokine which plays a key role in carcinogenesis and tumor progression. IL ‐1 is subject to regulation by components of the IL ‐1 and IL ‐1 receptor ( ILR ) families. Negative regulators include a decoy receptor ( IL ‐1R2), receptor antagonists ( IL ‐1Ra), IL ‐1R8, and anti‐inflammatory IL ‐37. IL ‐1 acts at different levels in tumor initiation and progression, including driving chronic non‐resolving inflammation, tumor angiogenesis, activation of the IL ‐17 pathway, induction of myeloid‐derived suppressor cells ( MDSC ) and macrophage recruitment, invasion and metastasis. Based on initial clinical results, the translation potential of IL ‐1 targeting deserves extensive analysis.